PF-06463922 + Crizotinib
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Conditions
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Trial Timeline
Jan 8, 2014 → May 24, 2023
NCT ID
NCT01970865About PF-06463922 + Crizotinib
PF-06463922 + Crizotinib is a phase 1/2 stage product being developed by Pfizer for ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT01970865. Target conditions include ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC.
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01970865 | Phase 1/2 | Completed |
Competing Products
9 competing products in ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crizotinib + Pembrolizumab | Merck | Phase 1 | 21 |
| Ceritinib (LDK378) + Nivolumab | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 27 |
| Ceritinib | Novartis | Phase 2 | 35 |
| ceritinib + warfarin + midazolam | Novartis | Phase 1 | 29 |
| PF-02341066 + Rifampin + Itraconazole | Pfizer | Phase 1 | 29 |
| Lortlatinib | Pfizer | Pre-clinical | 26 |
| Lorlatinib | Pfizer | Phase 2 | 31 |
| crizotinib + alectinib + brigatinib + ceritinib + lorlatinib | Pfizer | Pre-clinical | 26 |